Analysis of Intra-Tumoral Macrophages and T Cells in Non-Small Cell Lung Cancer (NSCLC) Indicates a Role for Immune

Anders Tøndell1,2, Yashwanth Subbannayya2,3, Sissel Gyrid Freim Wahl2,4

  • 1Department of Thoracic Medicine, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway.

Cancers
|April 30, 2021
PubMed

Insights

Researchers mapped immune cells in non-small cell lung carcinoma (NSCLC) to find new ways to improve immunotherapy. They identified novel immune checkpoints like CD200/CD200R1 and LILRs, offering new targets for cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Non-small cell lung carcinoma (NSCLC) is a major cause of cancer deaths.
  • Current immunotherapies are effective only in a subset of NSCLC patients.
  • Identifying novel immunosuppressive mechanisms is crucial for enhancing NSCLC immunotherapy.

Purpose of the Study:

  • To investigate gene expression profiles of immune cells within NSCLC tumors.
  • To identify novel immune checkpoints and immunosuppressive pathways in the NSCLC tumor microenvironment.
  • To explore the role of tumor-associated macrophages in NSCLC immunosuppression.

Main Methods:

  • Transcriptome analysis of macrophages, CD4+, and CD8+ T cells from NSCLC patients and healthy tissue.
  • Gene Ontology (GO) term enrichment analysis.
  • Weighted correlation network analysis.

Main Results:

  • Differential gene expression was observed in immune cells from NSCLC, particularly in myeloid-lymphocyte interactions.
  • Several immunosuppressive molecules and pathways were identified in tumor-associated macrophages.
  • Novel data on the expression of the CD200/CD200R1 pathway and leukocyte immunoglobulin-like receptors (LILRs) in immune cells were reported.

Conclusions:

  • Tumor-associated macrophages are key mediators of immunosuppression in NSCLC.
  • The CD200/CD200R1 pathway and LILRs represent potential novel innate immune checkpoints.
  • Targeting these pathways may enhance anti-tumor T cell responses and improve NSCLC immunotherapy outcomes.

Related Concept Videos